US Patent Issued to INVOX PHARMA on June 3 for "Mesothelin and CD137 binding molecules" (British Inventors)

ALEXANDRIA, Va., June 4 -- United States Patent no. 12,319,739, issued on June 3, was assigned to INVOX PHARMA Ltd. (London).

"Mesothelin and CD137 binding molecules" was invented by Jose Munoz-Olaya (Cambridge, Great Britain), Mihriban Tuna (Cambridge, Great Britain), Remi Fertin (Cambridge, Great Britain), Claire Reader (Cambridge, Great Britain), Francisca Wollerton (Cambridge, Great Britain) and Neil Brewis (Cambridge, Great Britain).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to antibody molecules that bind both mesothelin (MSLN) and CD137. The antibody molecules comprise a CDR-based binding site for MSLN, and a CD137 antigen-binding site located in a constant domain of t...